JP4989811B2 - 副甲状腺ホルモンおよび骨吸収抑制剤を含む複合型薬学的製剤 - Google Patents
副甲状腺ホルモンおよび骨吸収抑制剤を含む複合型薬学的製剤 Download PDFInfo
- Publication number
- JP4989811B2 JP4989811B2 JP50425999A JP50425999A JP4989811B2 JP 4989811 B2 JP4989811 B2 JP 4989811B2 JP 50425999 A JP50425999 A JP 50425999A JP 50425999 A JP50425999 A JP 50425999A JP 4989811 B2 JP4989811 B2 JP 4989811B2
- Authority
- JP
- Japan
- Prior art keywords
- administration
- bone resorption
- months
- bone
- resorption inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000199 parathyroid hormone Substances 0.000 title claims abstract description 91
- 102000003982 Parathyroid hormone Human genes 0.000 title claims abstract description 90
- 108090000445 Parathyroid hormone Proteins 0.000 title claims abstract description 90
- 229960001319 parathyroid hormone Drugs 0.000 title claims abstract description 82
- 229940078581 Bone resorption inhibitor Drugs 0.000 title claims description 35
- 239000000825 pharmaceutical preparation Substances 0.000 title claims description 5
- 238000011282 treatment Methods 0.000 claims abstract description 35
- 208000001132 Osteoporosis Diseases 0.000 claims abstract description 15
- 239000003814 drug Substances 0.000 claims abstract description 11
- 238000004519 manufacturing process Methods 0.000 claims abstract description 6
- 210000000988 bone and bone Anatomy 0.000 claims description 49
- 238000000034 method Methods 0.000 claims description 26
- 229940122361 Bisphosphonate Drugs 0.000 claims description 16
- 150000004663 bisphosphonates Chemical group 0.000 claims description 16
- 201000010099 disease Diseases 0.000 claims description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 229940011871 estrogen Drugs 0.000 claims description 8
- 239000000262 estrogen Substances 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 102000055006 Calcitonin Human genes 0.000 claims description 7
- 108060001064 Calcitonin Proteins 0.000 claims description 7
- 229930003316 Vitamin D Natural products 0.000 claims description 7
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 7
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims description 7
- 229960004015 calcitonin Drugs 0.000 claims description 7
- 238000009472 formulation Methods 0.000 claims description 7
- 235000019166 vitamin D Nutrition 0.000 claims description 7
- 239000011710 vitamin D Substances 0.000 claims description 7
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 7
- 229940046008 vitamin d Drugs 0.000 claims description 7
- 159000000007 calcium salts Chemical class 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 claims description 4
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims description 4
- 229940062527 alendronate Drugs 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- ZQZFYGIXNQKOAV-OCEACIFDSA-N Droloxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=C(O)C=CC=1)\C1=CC=C(OCCN(C)C)C=C1 ZQZFYGIXNQKOAV-OCEACIFDSA-N 0.000 claims description 2
- JJKOTMDDZAJTGQ-DQSJHHFOSA-N Idoxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN2CCCC2)=CC=1)/C1=CC=C(I)C=C1 JJKOTMDDZAJTGQ-DQSJHHFOSA-N 0.000 claims description 2
- 229950004203 droloxifene Drugs 0.000 claims description 2
- 229950002248 idoxifene Drugs 0.000 claims description 2
- XZEUAXYWNKYKPL-WDYNHAJCSA-N levormeloxifene Chemical compound C1([C@H]2[C@@H](C3=CC=C(C=C3OC2(C)C)OC)C=2C=CC(OCCN3CCCC3)=CC=2)=CC=CC=C1 XZEUAXYWNKYKPL-WDYNHAJCSA-N 0.000 claims description 2
- 229950002728 levormeloxifene Drugs 0.000 claims description 2
- 229960004622 raloxifene Drugs 0.000 claims description 2
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 claims description 2
- 229960001603 tamoxifen Drugs 0.000 claims description 2
- 229960005026 toremifene Drugs 0.000 claims description 2
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 claims description 2
- 229940095743 selective estrogen receptor modulator Drugs 0.000 claims 6
- 239000000333 selective estrogen receptor modulator Substances 0.000 claims 6
- 230000030991 negative regulation of bone resorption Effects 0.000 claims 2
- 238000011321 prophylaxis Methods 0.000 claims 1
- 101001135770 Homo sapiens Parathyroid hormone Proteins 0.000 abstract description 8
- 101001135995 Homo sapiens Probable peptidyl-tRNA hydrolase Proteins 0.000 abstract description 8
- 102000058004 human PTH Human genes 0.000 abstract description 8
- 238000010254 subcutaneous injection Methods 0.000 abstract 1
- 239000007929 subcutaneous injection Substances 0.000 abstract 1
- 230000004913 activation Effects 0.000 description 18
- 230000037182 bone density Effects 0.000 description 16
- 230000009102 absorption Effects 0.000 description 10
- 238000010521 absorption reaction Methods 0.000 description 10
- 238000007634 remodeling Methods 0.000 description 10
- 230000024279 bone resorption Effects 0.000 description 8
- 230000007423 decrease Effects 0.000 description 8
- 208000006386 Bone Resorption Diseases 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000003263 anabolic agent Substances 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 230000011164 ossification Effects 0.000 description 6
- 206010065687 Bone loss Diseases 0.000 description 5
- 206010017076 Fracture Diseases 0.000 description 5
- 229940124325 anabolic agent Drugs 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 210000004705 lumbosacral region Anatomy 0.000 description 4
- 210000000963 osteoblast Anatomy 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 210000002436 femur neck Anatomy 0.000 description 3
- 210000002997 osteoclast Anatomy 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 208000010392 Bone Fractures Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 208000029725 Metabolic bone disease Diseases 0.000 description 2
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 230000001195 anabolic effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000002617 bone density conservation agent Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 230000001009 osteoporotic effect Effects 0.000 description 2
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 102000017631 Calcitonin-like Human genes 0.000 description 1
- 108050005865 Calcitonin-like Proteins 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010067572 Oestrogenic effect Diseases 0.000 description 1
- 206010049088 Osteopenia Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- -1 alendronate Chemical class 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000123 anti-resoprtive effect Effects 0.000 description 1
- 238000011444 antiresorptive therapy Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 description 1
- 229960002286 clodronic acid Drugs 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000004821 effect on bone Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 239000002834 estrogen receptor modulator Substances 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000002188 osteogenic effect Effects 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 210000002990 parathyroid gland Anatomy 0.000 description 1
- 108010073509 parathyroid hormone (1-31) Proteins 0.000 description 1
- 108010073230 parathyroid hormone (1-38) Proteins 0.000 description 1
- 108010060933 parathyroid hormone (28-48) Proteins 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- OGBMKVWORPGQRR-UMXFMPSGSA-N teriparatide Chemical compound C([C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CNC=N1 OGBMKVWORPGQRR-UMXFMPSGSA-N 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/452—Piperidinium derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9702401-2 | 1997-06-19 | ||
| SE9702401A SE9702401D0 (sv) | 1997-06-19 | 1997-06-19 | Pharmaceutical use |
| PCT/SE1998/001095 WO1998057656A1 (en) | 1997-06-19 | 1998-06-08 | A combined pharmaceutical preparation comprising parathyroid hormone and a bone resorption inhibitor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010000066A Division JP5525825B2 (ja) | 1997-06-19 | 2010-01-04 | 副甲状腺ホルモンおよび骨吸収抑制剤を含む複合型薬学的製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002504140A JP2002504140A (ja) | 2002-02-05 |
| JP2002504140A5 JP2002504140A5 (enExample) | 2005-09-08 |
| JP4989811B2 true JP4989811B2 (ja) | 2012-08-01 |
Family
ID=20407482
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP50425999A Expired - Fee Related JP4989811B2 (ja) | 1997-06-19 | 1998-06-08 | 副甲状腺ホルモンおよび骨吸収抑制剤を含む複合型薬学的製剤 |
| JP2010000066A Expired - Fee Related JP5525825B2 (ja) | 1997-06-19 | 2010-01-04 | 副甲状腺ホルモンおよび骨吸収抑制剤を含む複合型薬学的製剤 |
| JP2013206919A Pending JP2014015479A (ja) | 1997-06-19 | 2013-10-02 | 副甲状腺ホルモンおよび骨吸収抑制剤を含む複合型薬学的製剤 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010000066A Expired - Fee Related JP5525825B2 (ja) | 1997-06-19 | 2010-01-04 | 副甲状腺ホルモンおよび骨吸収抑制剤を含む複合型薬学的製剤 |
| JP2013206919A Pending JP2014015479A (ja) | 1997-06-19 | 2013-10-02 | 副甲状腺ホルモンおよび骨吸収抑制剤を含む複合型薬学的製剤 |
Country Status (14)
| Country | Link |
|---|---|
| US (8) | US6284730B1 (enExample) |
| EP (2) | EP1473040B1 (enExample) |
| JP (3) | JP4989811B2 (enExample) |
| AT (2) | ATE447410T1 (enExample) |
| AU (1) | AU753477B2 (enExample) |
| CA (2) | CA2698626C (enExample) |
| CY (1) | CY1110287T1 (enExample) |
| DE (2) | DE69826132T2 (enExample) |
| DK (2) | DK1473040T3 (enExample) |
| ES (2) | ES2335404T3 (enExample) |
| PT (2) | PT1473040E (enExample) |
| SE (1) | SE9702401D0 (enExample) |
| WO (1) | WO1998057656A1 (enExample) |
| ZA (1) | ZA984947B (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010100644A (ja) * | 1997-06-19 | 2010-05-06 | Nps Pharmaceuticals Inc | 副甲状腺ホルモンおよび骨吸収抑制剤を含む複合型薬学的製剤 |
| US20220249620A1 (en) * | 2019-03-29 | 2022-08-11 | Seoul National University Hospital | Composition comprising recombinant parathyroid hormone for healing after rotator cuff repair |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL153229A0 (en) | 2000-06-20 | 2003-07-06 | Novartis Ag | Method of administering bisphosphonates |
| CA2372450A1 (en) * | 2001-05-10 | 2001-09-19 | Pharmaceutical Partners Of Canada Inc. | Liquid injectable formulation of disodium pamidronate |
| NZ529439A (en) | 2001-06-01 | 2005-11-25 | Novartis Ag | Method for orally administering parathyroid hormone (PTH) |
| US6827250B2 (en) * | 2001-06-28 | 2004-12-07 | Microchips, Inc. | Methods for hermetically sealing microchip reservoir devices |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| AU2003278766A1 (en) * | 2002-09-04 | 2004-03-29 | Microchips, Inc. | Method and device for the controlled delivery of parathyroid hormone |
| ES2421139T3 (es) | 2003-07-30 | 2013-08-29 | Rigel Pharmaceuticals, Inc. | Compuestos de 2,4-pirimidindiamina para su uso en el tratamiento o la prevención de enfermedades autoinmunitarias |
| US20050119183A1 (en) * | 2003-11-12 | 2005-06-02 | Nps Allelix Corp. | Method for treating bone loss using parathyroid hormone |
| US7488316B2 (en) | 2005-01-25 | 2009-02-10 | Microchips, Inc. | Control of drug release by transient modification of local microenvironments |
| JP2008543855A (ja) | 2005-06-13 | 2008-12-04 | ライジェル ファーマシューティカルズ， インコーポレイテッド | 変形性骨疾患を処置するための方法および組成物 |
| EP1734251B1 (en) * | 2005-06-17 | 2007-01-24 | MAGNETI MARELLI POWERTRAIN S.p.A. | Fuel injector |
| CN101355959B (zh) * | 2005-11-10 | 2013-02-27 | 密歇根理工大学管理委员会 | 黑熊甲状旁腺素和使用黑熊甲状旁腺素的方法 |
| WO2010115932A1 (en) * | 2009-04-08 | 2010-10-14 | Novartis Ag | Combination for the treatment of bone loss |
| ES2843649T3 (es) * | 2009-09-09 | 2021-07-20 | Asahi Kasei Pharma Corp | Agente terapéutico/profiláctico que contiene PTH para la osteoporosis, caracterizado porque la PTH se administra una vez por semana en una dosis unitaria de 200 unidades |
| EP2509996A1 (en) | 2009-12-07 | 2012-10-17 | Michigan Technological University | Black bear parathyroid hormone and methods of using black bear parathyroid hormone |
| US10064890B2 (en) * | 2011-12-13 | 2018-09-04 | Amorphical Ltd. | Amorphous calcium carbonate for the treatment of calcium malabsorption and metabolic bone disorders |
| DK3265115T3 (da) * | 2015-03-03 | 2022-09-05 | Radius Health Inc | Abaloparatid kombineret med alendronat til reduktion af ikke-vertebrale knoglebrud |
| RU2748976C2 (ru) | 2015-06-04 | 2021-06-02 | Аморфикал Лтд. | Композиции аморфного карбоната кальция для ингаляции, подъязычного или трансбуккального введения |
| US11052108B2 (en) | 2016-10-25 | 2021-07-06 | Amorphical Ltd. | Amorphous calcium carbonate for treating a leukemia |
| CA3144221A1 (en) | 2019-07-23 | 2021-01-28 | Amorphical Ltd | Amorphous calcium carbonate for improving athletic performance |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3768177A (en) | 1972-08-02 | 1973-10-30 | R Thomas | Educational device |
| US3886132A (en) | 1972-12-21 | 1975-05-27 | Us Health | Human parathyroid hormone |
| US4468464A (en) | 1974-11-04 | 1984-08-28 | The Board Of Trustees Of The Leland Stanford Junior University | Biologically functional molecular chimeras |
| US4237224A (en) | 1974-11-04 | 1980-12-02 | Board Of Trustees Of The Leland Stanford Jr. University | Process for producing biologically functional molecular chimeras |
| US4105602A (en) | 1975-02-10 | 1978-08-08 | Armour Pharmaceutical Company | Synthesis of peptides with parathyroid hormone activity |
| US4016314A (en) | 1975-06-26 | 1977-04-05 | Hallco Inc. | Embroidered fruit bowl wall hanging and kit for making same |
| US4264731A (en) | 1977-05-27 | 1981-04-28 | The Regents Of The University Of California | DNA Joining method |
| US4366246A (en) | 1977-11-08 | 1982-12-28 | Genentech, Inc. | Method for microbial polypeptide expression |
| US4199060A (en) | 1978-07-20 | 1980-04-22 | Howard Hardware Products, Inc. | Lock installation kit |
| US4425437A (en) | 1979-11-05 | 1984-01-10 | Genentech, Inc. | Microbial polypeptide expression vehicle |
| US4338397A (en) | 1980-04-11 | 1982-07-06 | President And Fellows Of Harvard College | Mature protein synthesis |
| US4383066A (en) | 1980-04-15 | 1983-05-10 | Mitsubishi Gas Chemical Company, Inc. | Polyphenylene ether resin composition |
| JPS5825439B2 (ja) | 1980-12-30 | 1983-05-27 | 株式会社林原生物化学研究所 | ヒト副甲状腺ホルモンの製造方法 |
| US4394443A (en) | 1980-12-18 | 1983-07-19 | Yale University | Method for cloning genes |
| US4624926A (en) | 1981-01-02 | 1986-11-25 | The Research Foundation Of State University Of New York | Novel cloning vehicles for polypeptide expression in microbial hosts |
| NO163060C (no) | 1981-03-13 | 1990-03-28 | Damon Biotech Inc | Fremgangsmaate for fremstilling av substanser som dannes av levende celler som produserer interferoner eller antistoffer. |
| US4385212A (en) | 1981-10-05 | 1983-05-24 | Bell Telephone Laboratories Incorporated | Expandable communication terminal housing |
| US4424278A (en) | 1981-11-16 | 1984-01-03 | Research Corporation | Cancer detection procedure using an acyl carrier protein |
| US4532207A (en) | 1982-03-19 | 1985-07-30 | G. D. Searle & Co. | Process for the preparation of polypeptides utilizing a charged amino acid polymer and exopeptidase |
| US4546082A (en) | 1982-06-17 | 1985-10-08 | Regents Of The Univ. Of California | E. coli/Saccharomyces cerevisiae plasmid cloning vector containing the alpha-factor gene for secretion and processing of hybrid proteins |
| US4595658A (en) | 1982-09-13 | 1986-06-17 | The Rockefeller University | Method for facilitating externalization of proteins synthesized in bacteria |
| EP0119247A1 (en) | 1982-09-15 | 1984-09-26 | Immuno Nuclear Corporation | Production of mature proteins in transformed yeast |
| DE3312928A1 (de) | 1983-04-11 | 1984-11-22 | Gesellschaft für Biotechnologische Forschung mbH (GBF), 3300 Braunschweig | Human-parathormon produzierende hybridvektoren und human-parathormongen |
| NZ207926A (en) | 1983-04-25 | 1988-04-29 | Genentech Inc | Use of yeast #a#-factor to assist in expression of proteins heterologus to yeast |
| US4588684A (en) | 1983-04-26 | 1986-05-13 | Chiron Corporation | a-Factor and its processing signals |
| US4637980A (en) | 1983-08-09 | 1987-01-20 | Smithkline Beckman Corporation | Externalization of products of bacteria |
| CA1213537A (en) | 1984-05-01 | 1986-11-04 | Canadian Patents And Development Limited - Societe Canadienne Des Brevets Et D'exploitation Limitee | Polypeptide expression method |
| ATE78515T1 (de) | 1984-10-05 | 1992-08-15 | Genentech Inc | Dna, zellkulturen und verfahren zur sekretion von heterologen proteinen und periplasmische proteinrueckgewinnung. |
| JPS61267528A (ja) | 1984-11-26 | 1986-11-27 | Yamanouchi Pharmaceut Co Ltd | 吸収促進剤を含有するカルシトニン経鼻剤 |
| WO1986003519A1 (en) | 1984-12-06 | 1986-06-19 | Synergen Biologicals, Inc. | Recombinant methods for production of serine protease inhibitors and dna sequences useful for same |
| US4812311A (en) | 1984-12-21 | 1989-03-14 | The Procter & Gamble Company | Kit for use in the treatment of osteoporosis |
| US4822609A (en) * | 1984-12-21 | 1989-04-18 | The Procter & Gamble Company | Treatment of osteoporosis |
| IL78342A (en) | 1985-04-04 | 1991-06-10 | Gen Hospital Corp | Pharmaceutical composition for treatment of osteoporosis in humans comprising a parathyroid hormone or a fragment thereof |
| US4994559A (en) | 1985-12-17 | 1991-02-19 | Synergen, Inc. | Human basic fibroblast growth factor |
| IE67035B1 (en) | 1986-07-08 | 1996-02-21 | Genetics Inst | Production and use of non-glycosylated IL-6 |
| US5010010A (en) | 1986-10-22 | 1991-04-23 | Selmer-Sande, A.S. | Production of human parathyroid hormone from microorganisms |
| US5420242A (en) | 1986-10-22 | 1995-05-30 | Kaare M. Gautvik | Production of human parathyroid hormone from microorganisms |
| EP0329693A4 (en) | 1986-10-30 | 1989-09-26 | Synergen Biolog Inc | HUMAN PANCREAS SECRETIONAL TRYPSIN INHIBITORS, MANUFACTURED BY DNA RECOMBINATION METHODS AND METHOD FOR THEIR PRODUCTION. |
| FI77278C (fi) | 1986-10-31 | 1989-02-10 | Ahlstroem Oy | Foerfarande och anordning foer foerbraenning av sodasvartlut. |
| US4833125A (en) | 1986-12-05 | 1989-05-23 | The General Hospital Corporation | Method of increasing bone mass |
| FR2618914B1 (fr) | 1987-07-31 | 1991-12-06 | Alain Souloumiac | Perfectionnements apportes aux interrupteurs optomagnetiques |
| US5059587A (en) | 1987-08-03 | 1991-10-22 | Toyo Jozo Company, Ltd. | Physiologically active peptide composition for nasal administration |
| JPH0649655B2 (ja) | 1987-11-12 | 1994-06-29 | シェリング・コーポレーション | Ｇｍ‐ｃｓｆによる骨形成の促進 |
| US4904584A (en) | 1987-12-23 | 1990-02-27 | Genetics Institute, Inc. | Site-specific homogeneous modification of polypeptides |
| US5223407A (en) | 1988-08-31 | 1993-06-29 | Allelix Inc. | Excretion of heterologous proteins from e. coli |
| US5011678A (en) | 1989-02-01 | 1991-04-30 | California Biotechnology Inc. | Composition and method for administration of pharmaceutically active substances |
| USRE37919E1 (en) | 1989-05-12 | 2002-12-03 | The General Hospital Corporation | Recombinant DNA method for production of parathyroid hormone |
| US5171670A (en) | 1989-05-12 | 1992-12-15 | The General Hospital Corporation | Recombinant dna method for production of parathyroid hormone |
| DE3935738A1 (de) | 1989-10-27 | 1991-05-08 | Forssmann Wolf Georg | Arzneimittel, enthaltend das humane parathormon-fragment (1-37) als aktiven wirkstoff |
| US5744444A (en) * | 1989-10-27 | 1998-04-28 | Haemopep Pharma Gmbh | HPTH-fragment-(1-37), the preparation thereof, medicaments containing same and the use thereof |
| GB9020544D0 (en) | 1990-09-20 | 1990-10-31 | Sandoz Ltd | Improvements in or relating to organic compounds |
| ES2099245T3 (es) * | 1990-11-26 | 1997-05-16 | Robert R Recker | Tratamiento de la osteoporosis usando factor de liberacion de hormona de crecimiento (grf) en combinacion con hormona paratiroidea (pth). |
| US5118667A (en) | 1991-05-03 | 1992-06-02 | Celtrix Pharmaceuticals, Inc. | Bone growth factors and inhibitors of bone resorption for promoting bone formation |
| US5563122A (en) * | 1991-12-09 | 1996-10-08 | Asahi Kasei Kogyo Kabushiki Kaisha | Stabilized parathyroid hormone composition |
| NZ246456A (en) | 1991-12-17 | 1997-03-24 | Procter & Gamble Pharma | Use of bone active phosphonate and a parathyroid hormone to prepare medicaments for a thirty day treatment regimen for osteoporosis |
| IT1255723B (it) | 1992-10-09 | 1995-11-13 | Uso di paratormone,suoi frammenti biologicamente attivi e peptidi correlati, per la preparazione di composizioni farmaceutiche utili nella prevenzione e terapia dell'aborto e del parto pretermine ed in generale per il trattamento della gestazione | |
| TW303299B (enExample) | 1993-07-22 | 1997-04-21 | Lilly Co Eli | |
| US5496801A (en) * | 1993-12-23 | 1996-03-05 | Allelix Biopharmaceuticals Inc. | Parathyroid hormone formulation |
| JP2001503728A (ja) | 1994-09-09 | 2001-03-21 | ザ、プロクター、エンド、ギャンブル、カンパニー | 骨粗鬆症治療用のエストロゲン及び副甲状腺ホルモン |
| EP0779812A4 (en) * | 1994-09-09 | 1997-09-10 | Procter & Gamble | METHOD FOR TREATING OSTEOPOROSIS USING BONE-ACTIVE PHOSPHONATES AND PARATHORMONE |
| US5747456A (en) * | 1994-12-19 | 1998-05-05 | Beth Israel Deaconess Medical Center | Continuous low-dose administration of parathyroid hormone or its agonist |
| US5550134A (en) | 1995-05-10 | 1996-08-27 | Eli Lilly And Company | Methods for inhibiting bone loss |
| US5599822A (en) | 1995-06-06 | 1997-02-04 | Eli Lilly And Company | Methods for minimizing bone loss |
| IL120270A0 (en) | 1996-02-28 | 1997-06-10 | Pfizer | Combination therapy to treat osteoporosis |
| HN1996000101A (es) * | 1996-02-28 | 1997-06-26 | Inc Pfizer | Terapia combinada para la osteoporosis |
| US5945412A (en) | 1996-12-09 | 1999-08-31 | Merck & Co., Inc. | Methods and compositions for preventing and treating bone loss |
| SE9702401D0 (sv) * | 1997-06-19 | 1997-06-19 | Astra Ab | Pharmaceutical use |
-
1997
- 1997-06-19 SE SE9702401A patent/SE9702401D0/xx unknown
-
1998
- 1998-06-08 DK DK04017622.4T patent/DK1473040T3/da active
- 1998-06-08 CA CA2698626A patent/CA2698626C/en not_active Expired - Fee Related
- 1998-06-08 DK DK98929965T patent/DK1001802T3/da active
- 1998-06-08 ES ES04017622T patent/ES2335404T3/es not_active Expired - Lifetime
- 1998-06-08 AT AT04017622T patent/ATE447410T1/de active
- 1998-06-08 AT AT98929965T patent/ATE275419T1/de active
- 1998-06-08 US US09/125,247 patent/US6284730B1/en not_active Expired - Lifetime
- 1998-06-08 ZA ZA984947A patent/ZA984947B/xx unknown
- 1998-06-08 JP JP50425999A patent/JP4989811B2/ja not_active Expired - Fee Related
- 1998-06-08 PT PT04017622T patent/PT1473040E/pt unknown
- 1998-06-08 AU AU79458/98A patent/AU753477B2/en not_active Ceased
- 1998-06-08 DE DE69826132T patent/DE69826132T2/de not_active Expired - Lifetime
- 1998-06-08 WO PCT/SE1998/001095 patent/WO1998057656A1/en not_active Ceased
- 1998-06-08 CA CA2294101A patent/CA2294101C/en not_active Expired - Fee Related
- 1998-06-08 ES ES98929965T patent/ES2229511T3/es not_active Expired - Lifetime
- 1998-06-08 PT PT98929965T patent/PT1001802E/pt unknown
- 1998-06-08 EP EP04017622A patent/EP1473040B1/en not_active Expired - Lifetime
- 1998-06-08 DE DE69841279T patent/DE69841279D1/de not_active Expired - Lifetime
- 1998-06-08 EP EP98929965A patent/EP1001802B1/en not_active Expired - Lifetime
-
2001
- 2001-08-31 US US09/942,661 patent/US20020002135A1/en not_active Abandoned
-
2003
- 2003-03-18 US US10/389,797 patent/US7018982B2/en not_active Expired - Fee Related
-
2005
- 2005-12-19 US US11/305,339 patent/US7507715B2/en not_active Expired - Fee Related
-
2009
- 2009-01-09 US US12/351,558 patent/US7749543B2/en not_active Expired - Fee Related
-
2010
- 2010-01-04 JP JP2010000066A patent/JP5525825B2/ja not_active Expired - Fee Related
- 2010-01-29 CY CY20101100091T patent/CY1110287T1/el unknown
- 2010-06-23 US US12/822,089 patent/US8153588B2/en not_active Expired - Fee Related
-
2012
- 2012-02-24 US US13/405,093 patent/US8765674B2/en not_active Expired - Fee Related
-
2013
- 2013-10-02 JP JP2013206919A patent/JP2014015479A/ja active Pending
-
2014
- 2014-05-22 US US14/285,437 patent/US20140256632A1/en not_active Abandoned
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010100644A (ja) * | 1997-06-19 | 2010-05-06 | Nps Pharmaceuticals Inc | 副甲状腺ホルモンおよび骨吸収抑制剤を含む複合型薬学的製剤 |
| US20220249620A1 (en) * | 2019-03-29 | 2022-08-11 | Seoul National University Hospital | Composition comprising recombinant parathyroid hormone for healing after rotator cuff repair |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5525825B2 (ja) | 副甲状腺ホルモンおよび骨吸収抑制剤を含む複合型薬学的製剤 | |
| AU5953894A (en) | Bisphosphonate/estrogen therapy for treating and preventing bone loss | |
| Patel | Current and potential future drug treatments for osteoporosis. | |
| WO1999004808A1 (en) | Dental remedies containing pth | |
| US6399592B1 (en) | Bishphosphonate/estrogen synergistic therapy for treating and preventing bone loss | |
| JPH0873376A (ja) | 骨粗鬆症治療薬 | |
| AU2002300896B2 (en) | Method of enhancing bone mineral density | |
| JP2003095974A (ja) | 骨形成を安全に促進させる医薬複合剤 | |
| Khosla et al. | Treatment options for osteoporosis | |
| HK1070816B (en) | Use of human parathyroid hormone | |
| HK1029738B (en) | A combined pharmaceutical preparation comprising parathyroid hormone and a bone resorption inhibitor | |
| Gennari | Calcitonin, bone-active isoflavones and vitamin D metabolites | |
| Hodsman | PTH peptides as anabolic agents in bone | |
| XU et al. | Recent advances in pharmacologic prevention and treatment of osteoporosis | |
| JPH1192395A (ja) | Ｐｔｈを含有する歯科治療剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20041210 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20041210 |
|
| A72 | Notification of change in name of applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A721 Effective date: 20061006 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080212 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080509 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080616 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080609 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080718 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080711 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080818 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080812 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20080829 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090901 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100104 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100316 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20100401 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20100729 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120501 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150511 Year of fee payment: 3 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |